Trial · NCT07900542
Middle East Study of Infections in Patients With Hematological Malignancies
NCT07900542, Recruiting, Hamad Medical Corporation
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Middle East Study of Infections in Patients With Hematological Malignancies. Trials, record NCT07900542. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07900542
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Middle East Study of Infections in Patients With Hematological Malignancies
- NCT number
- NCT07900542
- Status
- Recruiting
- Enrollment
- 1,000 participants, estimated
- Lead sponsor
- Hamad Medical Corporation
- Conditions
- Hematological Malignancy, Hematopoetic Stem Cell Transplantation, Bloodstream Infection
- Interventions
- No Intervention: Observational Cohort
- First posted
- 2026-10-28
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall bloodstream infection incidence per 1,000 patient days | 30 days | Overall bloodstream infection incidence per 1,000 patient days |
| Secondary | Persistent bloodstream infection | 30 days | The isolation of the same clinically significant microorganism(s) from blood cultures collected ≥7 days after the index blood culture. |
| Secondary | Microbiological relapse | 90 days | The recovery of the same species as that isolated from the index blood culture from a blood culture drawn anytime between discontinuation of active therapy for the index culture and the end of follow up. |
| Secondary | All-cause mortality | 30 days | All-cause mortality |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers12
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07900542
GET https://conductscience.org/api/trials/v1/NCT07900542/registered